Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine in Healthy Adults Aged 50 to 84 Years
Latest Information Update: 26 Sep 2024
At a glance
- Drugs SP-0202 (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate; Pneumococcal vaccine
- Indications Pneumococcal infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Sanofi
Most Recent Events
- 12 Apr 2022 Status changed from active, no longer recruiting to completed.
- 19 Oct 2021 Planned End Date changed from 1 Jan 2022 to 8 Jan 2022.
- 19 Oct 2021 Status changed from recruiting to active, no longer recruiting.